VCNX — Vaccinex Income Statement
0.000.00%
Last trade - 00:00- $1.78m
- $2.37m
- $0.60m
Annual income statement for Vaccinex, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.625 | 0.9 | 0.275 | 0.57 | 0.601 |
| Cost of Revenue | |||||
| Gross Profit | 0.623 | 0.9 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 29 | 22.5 | 20.2 | 23.5 | 19.3 |
| Operating Profit | -28.3 | -21.6 | -19.9 | -22.9 | -18.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -28.9 | -22.4 | -19.8 | -20.3 | -18.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -28.9 | -22.4 | -19.8 | -20.3 | -18.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -28.9 | -22.4 | -19.8 | -20.3 | -18.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28.9 | -22.4 | -19.8 | -20.3 | -18.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -322 | -169 | -98 | -43.7 | -8.88 |